# Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

> **NCT01838538** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Ovarian Cancer With Malignant Ascites

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** TC:paclitaxel + carboplatin

## Key facts

- **NCT ID:** NCT01838538
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2013-06
- **Final completion:** —
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2013-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838538, "Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01838538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*